| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 44 | 2023 | 304 | 5.020 |
Why?
|
| Papillomavirus Infections | 21 | 2020 | 149 | 2.790 |
Why?
|
| Cervical Intraepithelial Neoplasia | 25 | 2020 | 84 | 2.650 |
Why?
|
| Colposcopy | 23 | 2020 | 63 | 2.110 |
Why?
|
| Endometrial Neoplasms | 15 | 2024 | 189 | 2.080 |
Why?
|
| Ovarian Neoplasms | 16 | 2025 | 607 | 1.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2025 | 433 | 1.370 |
Why?
|
| Papillomaviridae | 15 | 2020 | 90 | 1.270 |
Why?
|
| Female | 109 | 2025 | 15624 | 1.210 |
Why?
|
| Mass Screening | 6 | 2019 | 158 | 1.180 |
Why?
|
| Adult | 68 | 2025 | 8024 | 1.130 |
Why?
|
| Middle Aged | 64 | 2025 | 7414 | 1.100 |
Why?
|
| Aged | 55 | 2025 | 5598 | 1.070 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2016 | 37 | 0.970 |
Why?
|
| Cervix Uteri | 9 | 2017 | 65 | 0.960 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 2065 | 0.940 |
Why?
|
| Lymph Nodes | 7 | 2023 | 103 | 0.940 |
Why?
|
| Humans | 113 | 2025 | 28851 | 0.900 |
Why?
|
| Urokinase-Type Plasminogen Activator | 3 | 2012 | 11 | 0.900 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2013 | 53 | 0.860 |
Why?
|
| Genital Neoplasms, Female | 8 | 2013 | 67 | 0.810 |
Why?
|
| Peptide Fragments | 3 | 2012 | 202 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2024 | 347 | 0.790 |
Why?
|
| Neoplasm Staging | 22 | 2021 | 480 | 0.720 |
Why?
|
| Precancerous Conditions | 7 | 2020 | 39 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2012 | 165 | 0.690 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 32 | 0.650 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 1 | 0.610 |
Why?
|
| Vulvar Neoplasms | 5 | 2012 | 25 | 0.600 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 28 | 0.600 |
Why?
|
| Biopsy | 10 | 2019 | 208 | 0.600 |
Why?
|
| Community Health Services | 1 | 2019 | 33 | 0.600 |
Why?
|
| Adolescent | 28 | 2021 | 3193 | 0.600 |
Why?
|
| Retrospective Studies | 28 | 2019 | 2635 | 0.590 |
Why?
|
| Peritoneal Neoplasms | 4 | 2013 | 80 | 0.580 |
Why?
|
| Early Detection of Cancer | 8 | 2020 | 137 | 0.580 |
Why?
|
| Disease Management | 1 | 2019 | 91 | 0.570 |
Why?
|
| Young Adult | 21 | 2021 | 2833 | 0.550 |
Why?
|
| Contraceptive Agents, Female | 4 | 2010 | 9 | 0.520 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2017 | 9 | 0.520 |
Why?
|
| Conization | 2 | 2007 | 11 | 0.510 |
Why?
|
| Vaginal Smears | 9 | 2018 | 45 | 0.500 |
Why?
|
| Carboplatin | 7 | 2025 | 121 | 0.490 |
Why?
|
| Carcinoma in Situ | 2 | 2013 | 46 | 0.480 |
Why?
|
| Sensitivity and Specificity | 14 | 2018 | 524 | 0.460 |
Why?
|
| Survival Rate | 10 | 2012 | 432 | 0.460 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2007 | 33 | 0.420 |
Why?
|
| Uterine Neoplasms | 5 | 2017 | 80 | 0.410 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2017 | 27 | 0.410 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 686 | 0.400 |
Why?
|
| Adenocarcinoma | 7 | 2018 | 300 | 0.400 |
Why?
|
| Lymphatic Metastasis | 9 | 2017 | 126 | 0.390 |
Why?
|
| Radiopharmaceuticals | 4 | 2017 | 74 | 0.390 |
Why?
|
| Paclitaxel | 6 | 2025 | 200 | 0.380 |
Why?
|
| Risk Assessment | 7 | 2018 | 631 | 0.380 |
Why?
|
| Disease-Free Survival | 9 | 2012 | 236 | 0.380 |
Why?
|
| United States | 12 | 2020 | 2222 | 0.370 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 72 | 0.350 |
Why?
|
| Prospective Studies | 8 | 2018 | 1280 | 0.330 |
Why?
|
| Positron-Emission Tomography | 2 | 2008 | 100 | 0.330 |
Why?
|
| Papanicolaou Test | 6 | 2018 | 25 | 0.320 |
Why?
|
| Lymph Node Excision | 11 | 2023 | 101 | 0.310 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2009 | 118 | 0.300 |
Why?
|
| Biomarkers, Tumor | 8 | 2014 | 415 | 0.290 |
Why?
|
| CA-125 Antigen | 1 | 2008 | 19 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2013 | 2426 | 0.290 |
Why?
|
| Genotype | 10 | 2018 | 461 | 0.280 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 1999 | 9 | 0.270 |
Why?
|
| Electrocoagulation | 1 | 2007 | 20 | 0.270 |
Why?
|
| Human papillomavirus 16 | 5 | 2018 | 24 | 0.270 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2007 | 3 | 0.260 |
Why?
|
| Contraception Behavior | 2 | 1998 | 17 | 0.250 |
Why?
|
| Vaginal Neoplasms | 3 | 2016 | 12 | 0.250 |
Why?
|
| Mucus | 1 | 2025 | 13 | 0.240 |
Why?
|
| DNA, Viral | 4 | 2014 | 63 | 0.230 |
Why?
|
| Pregnancy | 6 | 2019 | 1254 | 0.230 |
Why?
|
| Salmonella typhimurium | 1 | 2025 | 69 | 0.230 |
Why?
|
| Polysaccharides | 1 | 2025 | 64 | 0.230 |
Why?
|
| Neoplasm Grading | 6 | 2017 | 105 | 0.220 |
Why?
|
| Amifostine | 1 | 2003 | 5 | 0.210 |
Why?
|
| Topotecan | 1 | 2003 | 12 | 0.210 |
Why?
|
| Pregnancy in Adolescence | 2 | 2001 | 32 | 0.200 |
Why?
|
| Patient Selection | 2 | 2008 | 150 | 0.200 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 995 | 0.200 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 303 | 0.200 |
Why?
|
| Contraceptives, Postcoital | 2 | 2001 | 2 | 0.200 |
Why?
|
| Bacterial Proteins | 2 | 2025 | 497 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2010 | 233 | 0.200 |
Why?
|
| Neutropenia | 1 | 2003 | 41 | 0.200 |
Why?
|
| Physician's Role | 1 | 2003 | 29 | 0.200 |
Why?
|
| Risk Factors | 11 | 2013 | 2126 | 0.190 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2012 | 19 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2024 | 422 | 0.190 |
Why?
|
| Radiography | 5 | 2012 | 203 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 218 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2023 | 72 | 0.180 |
Why?
|
| Contraception | 1 | 2001 | 29 | 0.180 |
Why?
|
| Disease Progression | 7 | 2013 | 477 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 787 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2001 | 24 | 0.170 |
Why?
|
| Estradiol | 1 | 2001 | 176 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2001 | 40 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 3 | 2010 | 58 | 0.160 |
Why?
|
| Obesity | 3 | 2020 | 699 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2008 | 63 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2012 | 21 | 0.160 |
Why?
|
| Gynecology | 1 | 2001 | 60 | 0.160 |
Why?
|
| Inservice Training | 1 | 2000 | 10 | 0.160 |
Why?
|
| Taxoids | 2 | 2012 | 37 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1999 | 8 | 0.160 |
Why?
|
| Physical Education and Training | 1 | 2000 | 48 | 0.160 |
Why?
|
| Medroxyprogesterone Acetate | 3 | 2010 | 22 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2001 | 98 | 0.160 |
Why?
|
| Military Personnel | 1 | 2000 | 51 | 0.150 |
Why?
|
| Progestins | 2 | 1999 | 12 | 0.150 |
Why?
|
| Vibrio | 1 | 2019 | 4 | 0.150 |
Why?
|
| Physicians | 1 | 2020 | 83 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2019 | 14 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 123 | 0.150 |
Why?
|
| Cytodiagnosis | 1 | 2018 | 12 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 149 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 72 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 51 | 0.140 |
Why?
|
| Vagina | 2 | 2016 | 42 | 0.140 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 24 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2008 | 612 | 0.140 |
Why?
|
| Electrosurgery | 5 | 2012 | 15 | 0.140 |
Why?
|
| Curettage | 1 | 2017 | 4 | 0.140 |
Why?
|
| Surveys and Questionnaires | 6 | 2012 | 997 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 352 | 0.140 |
Why?
|
| Students | 1 | 2000 | 199 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 245 | 0.130 |
Why?
|
| Amenorrhea | 1 | 1997 | 5 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 1997 | 15 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 485 | 0.130 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 60 | 0.130 |
Why?
|
| Ovary | 1 | 1997 | 72 | 0.130 |
Why?
|
| Age Factors | 5 | 2010 | 737 | 0.130 |
Why?
|
| Oklahoma | 7 | 2013 | 1052 | 0.120 |
Why?
|
| Sexual Behavior | 4 | 2012 | 91 | 0.120 |
Why?
|
| Case Management | 1 | 2016 | 11 | 0.120 |
Why?
|
| Prognosis | 3 | 2008 | 811 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2008 | 739 | 0.120 |
Why?
|
| Specimen Handling | 2 | 2013 | 33 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2010 | 897 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2007 | 37 | 0.120 |
Why?
|
| Laparoscopy | 4 | 2002 | 156 | 0.120 |
Why?
|
| Conversion Disorder | 1 | 1995 | 2 | 0.120 |
Why?
|
| Contraceptive Devices | 1 | 1995 | 1 | 0.120 |
Why?
|
| Levonorgestrel | 1 | 1995 | 6 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1998 | 303 | 0.110 |
Why?
|
| Prevalence | 3 | 2020 | 518 | 0.110 |
Why?
|
| Personality Development | 1 | 1994 | 6 | 0.110 |
Why?
|
| Homosexuality, Female | 1 | 1994 | 4 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 1994 | 17 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 151 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 10 | 0.110 |
Why?
|
| Ki-67 Antigen | 2 | 2012 | 23 | 0.110 |
Why?
|
| Vulva | 1 | 2013 | 5 | 0.100 |
Why?
|
| Parenting | 1 | 1994 | 56 | 0.100 |
Why?
|
| Urine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Bone Density | 2 | 2010 | 101 | 0.100 |
Why?
|
| Polyploidy | 1 | 2013 | 10 | 0.100 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 10 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2014 | 90 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2025 | 106 | 0.100 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 21 | 0.100 |
Why?
|
| Niacinamide | 1 | 2013 | 32 | 0.100 |
Why?
|
| Sterilization, Tubal | 1 | 2012 | 6 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2013 | 83 | 0.100 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 5 | 0.090 |
Why?
|
| Leiomyoma | 1 | 2012 | 9 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 97 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 16 | 0.090 |
Why?
|
| Placebos | 2 | 2010 | 48 | 0.090 |
Why?
|
| Menstruation | 3 | 1998 | 9 | 0.090 |
Why?
|
| Viral Load | 1 | 2012 | 32 | 0.090 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 31 | 0.090 |
Why?
|
| Hysterectomy | 4 | 2013 | 86 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 31 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 110 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2013 | 1032 | 0.090 |
Why?
|
| Cisplatin | 3 | 2007 | 186 | 0.090 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2014 | 18 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 165 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2009 | 224 | 0.090 |
Why?
|
| Medical History Taking | 1 | 2011 | 20 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2010 | 8 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2010 | 8 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 7 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2010 | 33 | 0.080 |
Why?
|
| Retinoids | 2 | 2001 | 38 | 0.080 |
Why?
|
| Fatigue | 1 | 2010 | 64 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 31 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 131 | 0.080 |
Why?
|
| Referral and Consultation | 3 | 2014 | 98 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2025 | 523 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 11 | 0.070 |
Why?
|
| Pelvis | 3 | 2023 | 38 | 0.070 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 5 | 0.070 |
Why?
|
| Incidence | 4 | 2012 | 572 | 0.070 |
Why?
|
| Lymphedema | 1 | 2008 | 15 | 0.070 |
Why?
|
| Peritoneum | 1 | 2008 | 8 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 164 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 114 | 0.070 |
Why?
|
| Contraceptives, Oral | 2 | 2012 | 23 | 0.070 |
Why?
|
| Catheters, Indwelling | 2 | 2007 | 19 | 0.070 |
Why?
|
| Postmenopause | 1 | 2008 | 84 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2025 | 336 | 0.070 |
Why?
|
| Bridged-Ring Compounds | 1 | 2007 | 18 | 0.070 |
Why?
|
| Vesicovaginal Fistula | 1 | 2007 | 4 | 0.070 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 12 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 465 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 254 | 0.060 |
Why?
|
| Maintenance Chemotherapy | 1 | 2025 | 18 | 0.060 |
Why?
|
| Acetylgalactosamine | 1 | 2025 | 3 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2025 | 20 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2014 | 463 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2025 | 25 | 0.060 |
Why?
|
| Phthalazines | 1 | 2025 | 25 | 0.060 |
Why?
|
| Mucins | 1 | 2025 | 25 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 81 | 0.060 |
Why?
|
| Piperazines | 1 | 2025 | 50 | 0.060 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 31 | 0.060 |
Why?
|
| Metabolism | 2 | 1995 | 9 | 0.060 |
Why?
|
| Virulence | 1 | 2025 | 153 | 0.060 |
Why?
|
| Male | 5 | 2020 | 13921 | 0.060 |
Why?
|
| Human papillomavirus 18 | 2 | 2018 | 6 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2004 | 65 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 697 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 5 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1056 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2003 | 60 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 38 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2025 | 265 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 26 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 48 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2003 | 24 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 465 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 190 | 0.050 |
Why?
|
| Thallium | 1 | 2002 | 2 | 0.050 |
Why?
|
| Whole-Body Counting | 1 | 2002 | 3 | 0.050 |
Why?
|
| Iridium Radioisotopes | 1 | 2002 | 3 | 0.050 |
Why?
|
| Abdomen | 1 | 2002 | 41 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 144 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 91 | 0.050 |
Why?
|
| DNA | 1 | 2004 | 377 | 0.050 |
Why?
|
| Lipectomy | 1 | 2001 | 2 | 0.050 |
Why?
|
| Pregnancy, Unwanted | 1 | 2001 | 1 | 0.050 |
Why?
|
| Mutation | 1 | 2025 | 867 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2001 | 35 | 0.050 |
Why?
|
| Uterine Cervical Diseases | 2 | 2012 | 6 | 0.040 |
Why?
|
| Thiourea | 1 | 2001 | 17 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2003 | 163 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 73 | 0.040 |
Why?
|
| Benzoates | 1 | 2001 | 30 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 38 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 33 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 91 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 241 | 0.040 |
Why?
|
| Mentors | 1 | 2001 | 39 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 80 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 13 | 0.040 |
Why?
|
| Career Choice | 1 | 2001 | 53 | 0.040 |
Why?
|
| Carcinoma | 1 | 2001 | 74 | 0.040 |
Why?
|
| Wit and Humor as Topic | 1 | 2000 | 2 | 0.040 |
Why?
|
| Anthropology, Cultural | 1 | 2000 | 4 | 0.040 |
Why?
|
| Observation | 1 | 2000 | 5 | 0.040 |
Why?
|
| Relaxation Therapy | 1 | 2000 | 5 | 0.040 |
Why?
|
| Military Medicine | 1 | 2000 | 3 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2001 | 117 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 67 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1999 | 32 | 0.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1999 | 52 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1999 | 67 | 0.040 |
Why?
|
| Contraindications | 1 | 1999 | 13 | 0.040 |
Why?
|
| Logistic Models | 2 | 2012 | 410 | 0.040 |
Why?
|
| Self Concept | 1 | 2000 | 53 | 0.040 |
Why?
|
| Benzamides | 1 | 1999 | 39 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 1999 | 46 | 0.040 |
Why?
|
| Gene Library | 1 | 2019 | 45 | 0.040 |
Why?
|
| Estrogens | 1 | 1999 | 56 | 0.040 |
Why?
|
| Chromosomes, Bacterial | 1 | 2019 | 20 | 0.040 |
Why?
|
| Culture Media | 1 | 2019 | 99 | 0.040 |
Why?
|
| Social Support | 1 | 2000 | 129 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2020 | 245 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 134 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 431 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2000 | 429 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 93 | 0.040 |
Why?
|
| Genomics | 1 | 2019 | 124 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 497 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 312 | 0.040 |
Why?
|
| Confidentiality | 1 | 1998 | 10 | 0.030 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2017 | 3 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 490 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 226 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1997 | 14 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 93 | 0.030 |
Why?
|
| Probability | 2 | 2010 | 78 | 0.030 |
Why?
|
| Weight Gain | 1 | 1998 | 76 | 0.030 |
Why?
|
| Endometrium | 1 | 1997 | 39 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1997 | 43 | 0.030 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2016 | 2 | 0.030 |
Why?
|
| Child | 2 | 2010 | 2287 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 360 | 0.030 |
Why?
|
| Condoms | 1 | 1995 | 17 | 0.030 |
Why?
|
| Menstrual Cycle | 1 | 1995 | 24 | 0.030 |
Why?
|
| Psychosexual Development | 1 | 1994 | 2 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 1995 | 68 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 92 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2014 | 61 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2014 | 54 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Models, Biological | 2 | 2009 | 469 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 75 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2013 | 3 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 95 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2013 | 13 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 34 | 0.020 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 2 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2013 | 27 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 50 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 472 | 0.020 |
Why?
|
| Groin | 1 | 2012 | 3 | 0.020 |
Why?
|
| Myometrium | 1 | 2012 | 7 | 0.020 |
Why?
|
| Parity | 1 | 2012 | 50 | 0.020 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 9 | 0.020 |
Why?
|
| Brachytherapy | 2 | 2003 | 54 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 108 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 120 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 179 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 270 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 243 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2008 | 634 | 0.020 |
Why?
|
| Drug Implants | 1 | 2010 | 14 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 48 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2001 | 103 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 24 | 0.020 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Vaccines, Virosome | 1 | 2010 | 1 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 145 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2010 | 42 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 465 | 0.020 |
Why?
|
| Vitamin D | 1 | 2010 | 51 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 13 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 76 | 0.020 |
Why?
|
| Affect | 1 | 2010 | 85 | 0.020 |
Why?
|
| Fever | 1 | 2010 | 31 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Headache | 1 | 2010 | 34 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 100 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2009 | 4 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 314 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 147 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 33 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 302 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 15 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 326 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2009 | 67 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2009 | 10 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 59 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 67 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 138 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 477 | 0.020 |
Why?
|
| Women | 1 | 2008 | 12 | 0.020 |
Why?
|
| Automation | 1 | 2008 | 21 | 0.020 |
Why?
|
| Sutures | 1 | 2008 | 15 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 83 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 51 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 37 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 841 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 258 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2007 | 76 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2009 | 668 | 0.020 |
Why?
|
| Software | 1 | 2008 | 127 | 0.020 |
Why?
|
| Quality of Life | 1 | 2010 | 521 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 9 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 412 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 77 | 0.010 |
Why?
|
| Artifacts | 1 | 2005 | 51 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 194 | 0.010 |
Why?
|
| Lymphatic System | 1 | 2004 | 11 | 0.010 |
Why?
|
| Psychopathology | 1 | 1964 | 6 | 0.010 |
Why?
|
| Social Conditions | 1 | 1964 | 5 | 0.010 |
Why?
|
| Breast Diseases | 1 | 1964 | 7 | 0.010 |
Why?
|
| Classification | 1 | 1964 | 15 | 0.010 |
Why?
|
| Fiber Optic Technology | 1 | 2004 | 14 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 22 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 50 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fear | 1 | 1964 | 60 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 31 | 0.010 |
Why?
|
| Physical Examination | 1 | 1964 | 53 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 200 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 63 | 0.010 |
Why?
|
| Health Education | 1 | 1964 | 75 | 0.010 |
Why?
|
| Virion | 1 | 2003 | 6 | 0.010 |
Why?
|
| Capsules | 1 | 2003 | 8 | 0.010 |
Why?
|
| Plasminogen | 1 | 2003 | 8 | 0.010 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 8 | 0.010 |
Why?
|
| Palliative Care | 1 | 1964 | 86 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1964 | 116 | 0.010 |
Why?
|
| Particle Size | 1 | 2003 | 105 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 126 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 114 | 0.010 |
Why?
|
| Anxiety | 1 | 1964 | 158 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 80 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 18 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 2002 | 9 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2002 | 56 | 0.010 |
Why?
|
| Radiation Protection | 1 | 2002 | 17 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 2002 | 15 | 0.010 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2001 | 4 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 33 | 0.010 |
Why?
|
| Fenretinide | 1 | 2001 | 4 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 285 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 43 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 82 | 0.010 |
Why?
|
| Myocardium | 1 | 2002 | 196 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2001 | 55 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 391 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 36 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 222 | 0.010 |
Why?
|
| Length of Stay | 1 | 2001 | 245 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1999 | 5 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1999 | 24 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 1999 | 26 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 90 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 490 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 154 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 209 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 685 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1999 | 332 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1964 | 482 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 404 | 0.010 |
Why?
|
| Metaplasia | 1 | 1997 | 5 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 34 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 780 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 40 | 0.010 |
Why?
|
| Neoplasms | 1 | 1964 | 874 | 0.010 |
Why?
|
| Mice | 1 | 1999 | 4802 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 10684 | 0.000 |
Why?
|